Molecular genetics of plasma cholesteryl ester transfer protein

Current Opinion in Lipidology

Volumn 8, Issue 2, 1997, Pages 101-110

  Yamashita, Shizuya ^a   Sakai, Naohiko ^a   Hirano, Ken Ichi ^a   Arai, Takeshi ^a   Ishigami, Masato ^a   Maruyama, Takao ^a   Matsuzawa, Yuji ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LINOLEIC ACID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; LIPOPROTEIN METABOLISM; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN TRANSPORT; REVIEW; TRANSGENIC MOUSE;

ANIMALS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; GLYCOPROTEINS; HUMANS; LIPOPROTEINS; MICE; MICE, TRANSGENIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031007875     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199704000-00008     Document Type: Review

References (76)

1. Tall AR: Plasma cholesteryl ester transfer protein. J Lipid Res 1993, 34:1255-1274.
2. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996, 271:518-520.
3. Yen FY, Deckelbaum RJ, Mann CJ, Marcel YL, Milne RW, Tall AR: Inhibition of cholesteryl ester transfer protein activity by monoclonal antibody; effects on cholesteryl ester formation and neutral lipid mass transfer in human plasma. J Clin Invest 1989, 83:2018-2024.
4. Whitlock ME, Swenson TL, Ramakrishnan R, Leonard MT, Marcel YL, Milne RW, Tall AR: Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit; effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism. J Clin Invest 1989, 84:129-137.
5. Sugano M, Makino N: Changes in plasma lipoprotein cholesterol levels by antisense oligonucleotides against cholesteryl ester transfer protein in cholesterol-fed rabbits. J Biol Chem 1996, 271:19080-19083.
6. Zechner R, Dieplinger H, Steyrer E, Groener J, Calvert D, Kostner GM: In vitro formation of HDL-2 from HDL-3 and triacylglycerol-rich lipoproteins by the action of lecithin : cholesterol acyltransferase and cholesterol ester transfer protein. Biochim Biophys Acta 1987, 918:27-35.
7. Newnham HH, Barter PJ: Synergistic effects of lipid transfers and hepatic lipase in the formation of very small high-density lipoproteins during incubation of human plasma. Biochim Biophys Acta 1990, 1044:57-64.
8. Lagrost L, Athias A, Herbeth B, Guyard-Dangremont V, Artur Y, Paille F, Gambert P, Lallemant C: Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins; physiological relevance in alcoholic patients. J Biol Chem 1996, 271:19058-19065. Both CETP and phospholipid transfer protein are involved in the remodelling of HDL particles. This group showed that these two lipid transfer proteins may have opposite effects on the HDL interconversion process.
9. Sattler W, Stocker R: Greater selective uptake by HepG2 cells of high density lipoprotein cholesteryl ester hydroperoxides than of unoxidized cholesteryl esters. Biochem J 1993, 294:771-778.
10. Christison JK, Rye K-A, Stocker R: Exchange of oxidized cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer protein. J Lipid Res 1995, 36:2017-2026. CETP was demonstrated to be involved in the exchange of oxidized lipids between LDL and HDL. CETP may facilitate the removal and hepatic detoxication of oxidized lipids from atherosclerotic lesions.
11. Stein O, Halperin G, Stein Y: Cholesteryl ester efflux from extracellular and cellular elements of the arterial wall; model systems in culture with cholesteryl linoleyl ether. Arteriosclerosis 1986, 6:70-78.
12. Stein Y, Stein O, Olivecrona T, Halperin G: Putative role of cholesteryl ester transfer protein in removal of cholesteryl ester from vascular interstitium, studied in a model system in cell culture. Biochim Biophys Acta 1985, 834:336-345.
13. Drayna D, Jarnagin AS, McLean J, Henzel W, Kohr W, Fielding C, Lawn R: Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 1987, 327:632-634.
14. Nagashima M, McLean JW, Lawn RM: Cloning and mRNA tissue distribution of rabbit cholesteryl ester transfer protein. J Lipid Res 1988, 29:1643-1649.
15. Pape ME, Rehberg EF, Marotti KR, Melchior GW: Molecular cloning, sequence, and expression of cynomolgus monkey cholesteryl ester transfer protein; inverse correlation between hepatic cholesteryl ester transfer protein mRNA levels and plasma high density lipoprotein levels. Arterioscler Thromb 1991, 11:1759-1771.
16. Jiang XC, Moulin P, Quinet E, Goldberg IJ, Yacoub LK, Agellon LB, Compton D, Schnitzer-Polokoff R, Tall AR: Mammalian adipose tissue and muscle are major sources of lipid transfer protein mRNA. J Biol Chem 1991, 266:4631-4639.
17. Agellon L, Quinet E, Gillette T, Drayna D, Brown M, Tall AR: Organization of the human cholesteryl ester transfer protein gene. Biochemistry 1990, 29:1372-1376.
18. Day JR, Albers JJ, Lofton-Day CE, Gilbert TL, Ching AFT, Grant FJ, O'Hara PJ, Marcovina SM, Adolphson JL: Complete cDNA encoding human phospholipid transfer protein from human endothelial cells. J Biol Chem 1994, 269:9388-9391.
19. Tu A-Y, Deeb SS, Iwasaki L, Day JR, Albers JJ: Organization of human phospholipid transfer protein gene. Biochem Biophys Res Commun 1995, 207:552-558. This study showed a close similarity between the human phospholipid transfer protein and CETP genes in terms of gene sequence and genomic organization.
20. Shen GX, Zhang JY, Blanchard R, Zhang H-F, Hayden M, McPherson R, Angel A: Analysis of cholesteryl ester transfer activity in adipose tissue. Int J Obes 1996, 20(suppl 3):S114-S120.
21. Radeau T, Lau P, Robb M, McDonnell M, Ailhaud G, McPherson R: Cholesteryl ester transfer protein (CETP) mRNA abundance in human adipose tissue; relationship to cell size and membrane cholesterol content. J Lipid Res 1995, 36:2552-2561.
22. Faust RA, Tollefson JH, Chait A, Albers JJ: Regulation of LTP-I secretion from human monocyte-derived macrophages by differentiation and cholesterol accumulation in vitro. Biochim Biophys Acta 1990, 1042:404-409.
23. Richardson MA, Berg DT, Johnston PA, McClure D, Grinnell BW: Human liposarcoma cell line, SW872, secretes cholesteryl ester transfer protein in response to cholesterol. J Lipid Res 1996, 37:1162-1166.
24. Quinet E, Tall A, Ramakrishnan R, Rudel L: Plasma lipid transfer protein as a determinant of the atherogenicity of monkey plasma lipoproteins. J Clin Invest 1991, 87:1559-1566.
25. Pape ME, Ulrich RG, Rea TJ, Marotti KR, Melchior GW: Evidence that the nonparenchymal cells are the principal source of cholesteryl ester transfer protein in primates. J Biol Chem 1991, 266:12829-12831.
26. Agellon LB, Zhang P, Jiang XC, Mendelssohn L, Tall AR: The CCAAT/ enhancer-binding protein trans-activates the human cholesteryl ester transfer protein gene promoter. J Biol Chem 1992, 267:22336-22339.
27. Gaudet F, Ginsburg GS: Transcriptional regulation of the cholesteryl ester transfer protein gene by the orphan nuclear hormone receptor apolipoprotein AI regulatory protein-1. J Biol Chem 1995, 270:29916-29922. The promoter region for CETP gene contains nuclear hormone responsive elements required for transcriptional activity, including ARP-1 and its homologue Ear-3/COUP-TF.
28. Wang S, Deng L, Milne RW, Tall AR: Identification of a sequence within the C-terminal 26 amino acids of cholesteryl ester transfer protein responsible for binding a neutralizing antibody and necessary for neutral lipid transfer activity. J Biol Chem 1992, 267:17487-17490.
29. Fukasawa M, Aral H, Inoue K: Establishment of anti-human cholesteryl ester transfer protein monoclonal antibodies and radioimmunoassaying of the level of cholesteryl ester transfer protein in human plasma. J Biochem 1992, 111:696-698.
30. Wang S, Deng L, Brown ML, Agellon LB, Tall AR: Structure-function studies of human cholesteryl ester transfer protein by linker insertion scanning mutagenesis. Biochemistry 1991, 30:3484-3490.
31. Au-Young J, Fielding CJ: Synthesis and secretion of wild-type and mutant human plasma cholesteryl ester transfer protein in baculovirus-transfected insect cells; the carboxyl-terminal region is required for both lipoprotein binding and catalysis of transfer. Proc Natl Acad Sci U S A 1992, 89:4049-4098.
32. Wang S, Wang X, Deng L, Rassart E, Milne RW, Tall AR: Point mutagenesis of carboxyl-terminal amino acids of cholesteryl ester transfer protein. Opposite faces of an amphipathic helix important for cholesteryl ester transfer or for binding neutralizing antibody. J Biol Chem 1993, 268:1955-1959.
33. Stevenson SC, Wang S, Deng L, Tall AR: Human plasma cholesteryl ester transfer protein consists of a mixture of two forms reflecting variable glycosylation at asparagine 341. Biochemistry 1993, 32:5121-5126.
34. Kotake H, Li Q, Ohnishi T, Ko KWS, Agellon LB, Yokoyama S: Expression and secretion of rabbit plasma cholesteryl ester transfer protein by Pichia pastoris. J Lipid Res 1996, 37:599-605.
35. Inazu A, Quinet EM, Wang S, Brown ML, Stevenson S, Barr ML, Moulin P, Tall AR: Alternative splicing of the mRNA encoding the human cholesteryl ester transfer protein. Biochemistry 1992, 31:2352-2358.
36. Quinet E, Yang TP, Marinos C, Tall A: Inhibition of the cellular secretion of cholesteryl ester transfer protein by a variant protein formed by alternative splicing of mRNA. J Biol Chem 1993, 268:16891-16894.
37. Agellon LB, Walsh A, Hayek T, Moulin P, Jiang XC, Shelanski SA, Breslow JL, Tall AR: Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem 1991, 266:10796-10801.
38. Marotti KR, Castle CK, Murray RW, Rehberg EF, Polites HG, Melchior GW: The role of cholesteryl ester transfer protein in primate apolipoprotein A-I metabolism; insights from studies with transgenic mice. Arterioscler Thromb 1992, 12:736-744.
39. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW: Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993, 364:73-75.
40. Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall A: Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice; dependence on natural flanking sequences. J Clin Invest 1992, 90:1290-1295.
41. Jiang XC, Masucci-Magoulas L, Mar J, Lin M, Walsh A, Breslow JL, Tall A: Down regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein; mechanism to explain accumulation of lipoprotein B particles. J Biol Chem 1994, 268:27406-27412.
42. Hayek T, Chajek-Shaul T, Walsh A, Agellon LB, Moulin P, Tall AR, Breslow JL: An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of HDL cholesterol levels. J Clin Invest 1992, 90:505-510.
43. Hayek T, Azrolan N, Verdery RB, Walsh A, Chajek-Shaul T, Agellon LB, Tall AR, Breslow JL: Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism; studies in transgenic mice. J Clin Invest 1993, 92:1143-1152.
44. Masucci-Magoulas L, Plump A, Jiang XC, Walsh A, Breslow JL, Tall AR: Profound induction of hepatic cholesteryl ester transfer protein transgene expression in apolipoprotein E and low density lipoprotein receptor gene knockout mice; a novel mechanism signals changes in plasma cholesterol levels. J Clin Invest 1996, 97:154-161. In CETP transgenic mice mated with apo E or LDL receptor gene knockout mice, plasma CETP and hepatic CETP mRNA levels were markedly increased after cholesterol feeding. In CETP transgenic, CETP transgenic/apo E knockout, and CETP transgenic/LDL receptor knockout mice on different diets, plasma CETP and CETP mRNA levels were correlated with plasma cholesterol levels. Hepatic CETP gene expression may be controlled by a novel mechanism that senses changes in plasma cholesterol levels independent of apo E and LDL receptor levels.
45. Yang T-P, Agellon LB, Walsh A, Breslow JL, Tall AR: Alternative splicing of the human cholesteryl ester transfer protein gene in transgenic mice; exon exclusion modulates gene expression in response to dietary or developmental change. J Biol Chem 1996, 271:12603-12609.
46. Kurasawa T, Yokoyama S, Miyake Y, Yamamura T, Yamamoto A: Deficiency of serum cholesteryl ester transfer between high and low density lipoproteins in human serum and a case with decreased transfer rate in association with hyperalphalipoproteinemia. J BioChem 1985, 98:1499-1508.
47. Koizumi J, Mabuchi H, Yoshimura A, Michishita I, Takeda M, Itoh H, Sakai Y, Sakai T, Ueda K, Takeda R: Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinemia. Atherosclerosis 1985, 58:175-186.
48. Yamashita S, Matsuzawa Y, Okazaki M, Kako H, Yasugi T, Akioka H, Hirano K, Tarui S: Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity. Atherosclerosis 1988, 70:7-12.
49. Hirano K, Yamashita S, Kuga Y, Sakai N, Nozaki S, Kihara S, Aral T, Yanagi K, Takami S, Menju M et al.: Atherosclerotic disease in marked hyperalphalipoproteinemia; combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol 1995, 15:1849-1856. This study was the first demonstration of atherogenicity in CETP-deficient individuals. Atherosclerotic cardiovascular diseases were observed in CETP-deficient individuals despite extremely high HDL-cholesterol levels. These occur especially in those patients with a combined deficiency of CETP and HTGL, which have a synergistic role in the formation of small HDL particles.
50. Yamashita S, Sprecher DL, Sakai N, Matsuzawa Y, Tarui S, Hui DY: Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J Clin Invest 1990, 86:688-695.
51. Sakai N, Matsuzawa Y, Hirano K, Yamashita S, Nozaki S, Ueyama Y, Kubo M, Tarui S: Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency. Arterioscler Thromb 1991, 11:71-79.
52. Ishigami M, Yamashita S, Sakai N, Arai T, Hirano K, Hiraoka H, Takemura K, Matsuzawa Y: Large and cholesteryl ester-rich high density lipoproteins in cholesteryl ester transfer protein deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low density lipoproteins. J Biochem 1994, 116:257-262.
53. McPherson R, Agnani G, Lau P, Fruchart J-C, Edgar AD, Marcel YL: Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer; studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy. Arterioscler Thromb Vasc Biol 1996, 16:1340-1346.
54. Ohta T, Nakamura R, Takata K, Saito Y, Yamashita S, Horiuchi S, Matsuda I: Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency. J Lipid Res 1995, 36:696-704. This group described the LpA-I level which is decreased in CETP deficiency, and which results in a significant decrease in the efflux and LCAT-mediated esterification of cholesterol compared with normal control individuals.
55. Ikewaki K, Rader DJ, Sakamoto T, Nishiwaki M, Wakimoto N, Schaefer JR, Ishikawa T, Fairwell T, Zech LA, Nakamura H, Brewer HB Jr: Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest 1993, 92:1650-1658.
56. Ikewaki K, Nishiwaki M, Sakamoto T, Ishikawa T, Fairwell T, Zech LA, Nagano M, Nakamura H, Brewer HB Jr, Rader DJ: Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J Clin Invest 1995, 96:1573-1581.
57. Sakai N, Yamashita S, Hirano K, Ishigami M, Arai T, Kobayashi K, Funahashi T, Matsuzawa Y: Decreased affinity of low density lipoprotein (LDL) particles for LDL receptors in patients with cholesteryl ester transfer protein deficiency. Eur J Clin Invest 1995, 25:332-339. In this report, the apo B-containing triglyceride-rich LDL particles from CETP-deficient individuals are shown to have a lower affinity to LDL receptors than those from control individuals. Thus, CETP deficiency causes functional abnormalities of both HDL and LDL as well as compositional abnormalities of these Lps.
58. Yamashita S, Ishigami M, Arai T, Sakai N, Hirano K, Kameda-Takemura K, Tokunaga K, Matsuzawa Y: Very high density lipoprotein (VHDL) induced by plasma cholesteryl ester transfer protein (CETP) have a potent anti-atherogenic function. Ann N Y Acad Sci 1995, 748:606-608. CETP, together with HTGL, transforms the large HDL particles of CETP-deficient individuals into small ones, which have a potent antiatherogenic function in vitro.
59. Francone OL, Royer L, Haghpassand M: Increased preβ-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apo A-I) transgene. J Lipid Res 1996, 37:1268-1277. This report showed increased preβ-HDL levels, cholesterol efflux and LCAT-mediated esterification in vivo in mice expressing human CETP and human apo A-I transgenes.
60. Brown ML, Inazu A, Hesler CB, Agelon LB, Mann C, Whitlock MT, Marcel YL, Milne RW, Koizumi J, Mabuchi H et al., Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 1989, 342:448-451.
61. Yamashita S, Hui DY, Wetterau JR, Sprecher DL, Harmony JAK, Matsuzawa Y, Tarui S: Total deficiency of plasma cholesteryl ester transfer protein in subjects homozygous and heterozygous for the intron 14 splicing defect. Biochem Biophys Res Commun 1990, 170:1346-1351.
62. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruyama Y, Mabuchi H, Tall AR: Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990, 323:1234-1238.
63. Hirano K, Yamashita S, Funahashi T, Sakai N, Menju M, Ishigami M, Hiraoka H, Takemura K, Tokunaga K, Matsuzawa Y: Frequency of intron 14 splicing defect of cholesteryl ester transfer protein gene in the Japanese general population. Atherosclerosis 1993, 100:85-90.
64. Takahashi K, Jiang X-C, Sakai N, Yamashita S, Hirano K, Bujo H, Yamazaki H, Kusunoki J, Miura T, Kussie P et al.: A missense mutation in the cholesteryl ester transfer protein gene with dominant effects on plasma high density lipoproteins. J Clin Invest 1993, 92:2063-2064.
65. Sakai N, Yamashita S, Hirano K, Menju M, Arai T, Kobayashi K, Ishigami M, Yoshida Y, Hoshino T, Nakajima N et al.: Frequency of exon 15 missense mutation (442D:G) in cholesteryl ester transfer protein gene in hyperalphalipoproteinemic Japanese subjects. Atherosclerosis 1995, 114:139-145.
66. Inazu A, Jiang X, Haraki T, Yagi K, Kamon N, Koizumi J, Mabuchi H, Takeda R, Takata K, Moriyama Y et al.: Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J Clin Invest 1994, 94:1872-1882.
67. Gotoda T, Kinoshita M, Shimano H, Harada K, Shimada M, Ohsuga J, Teramoto T, Yazaki Y, Yamada N: Cholesteryl ester transfer protein deficiency caused by a nonsense mutation detected in the patient's macrophage mRNA. Biochem Biophys Res Commun 1993, 194:519-524.
68. Arai T, Yamashita S, Sakai N, Hirano K, Okada S, Ishigami M, Maruyama T, Yamane M, Kobayashi H, Nozaki S et al.: A novel nonsense mutation (G181X) in the human cholesteryl ester transfer protein gene in Japanese hyperalphalipoproteinemic subjects. J Lipid Res 1996, 37:2145-2154. The authors identified a novel nonsense mutation in the CETP gene. This mutation is common, but its frequency in hyperalphalipoproteinemic subjects is rather rare compared with the intron splicing defect and D442:G mutation.
69. Sakai N, Santamaria-Fojo S, Yamashita S, Matsuzawa Y, Brewer HB Jr: Exon 10 skipping caused by intron 10 splice donor site mutation in cholesteryl ester transfer protein gene results in abnormal downstream splice site selection. J Lipid Res 1996, 37:2065-2073. This paper identified another novel mutation in the CETP gene, which causes exon 10 skipping, resulting in abnormal downstream splice site selection.
70. Funke H, Wiebusch H, Fuer L, Muntoni S, Schulte H, Assmann G: Identification of mutations in the cholesteryl ester transfer protein in Europeans with elevated high density lipoprotein cholesterol. Circulation 1994, 90:1-241.
71. Tall AR: Plasma lipid transfer proteins. J Lipid Res 1986, 27:361-367.
72. Hirano K, Yamashita S, Sakai N, Arai T, Yoshida Y, Nozaki S, Kameda-Takemura K, Matsuzawa Y: Molecular defect and atherogenicity in cholesteryl ester transfer protein deficiency. Ann N Y Acad Sci 1995, 748:606-608.
73. Hirano K, Yamashita S, Arai T, Yoshida Y, Takemura K, Matsuzawa Y: Marked hyperalphalipoproteinemia is not a longevity syndrome: insights from a cohort study in a city where CETP deficiency accumulates [Abstract]. Atherosclerosis 1994, 109:229.
74. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR: Increased coronary heart disease in Japanese-American men with mutations in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996, 97:2917-2923. In this study of Japanese American men living in Hawaii, the incidence of coronary heart disease was higher in individuals with CETP mutations than in those without mutations, suggesting that CETP may be an antiatherogenic protein.
75. Hayek T, Masucci-Magoulas L, Jiang X, Walsh A, Rubin E, Breslow JL, Tall AR: Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 1995, 96:2071-2074. CETP overexpression inhibits the development of early atherosclerotic lesions in hypertriglyceridemic apo C-III transgenic mice.
76. Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ: Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 1993, 261:469-472.